We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Cytomyx Hldgs | CYX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.10 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.10 |
| Top Posts |
|---|
Posted at 25/1/2007 09:57 by safman morning..added CYX to my biotech portfollio, increasing uses of biomarkers in the industry.. one of the aspects, plus dir buying spree.. Do a little research on biomarkers and its increasing uses.. imo good luck.. saffy.. |
Posted at 28/11/2006 13:10 by safman irectorate ChangeRNS Number:8283M Cytomyx Holdings PLC 28 November 2006 CYTOMYX HOLDINGS PLC ("Cytomyx" or the "Company") New Loan, Board Changes and Appointment of European Distributor Cytomyx Holdings plc (AIM: CYX), announces that it has entered into a new loan agreement and the appointment of Cambridge BioScience Limited as its new European distributor. Several changes to the Board of Directors are also announced today. The Company has entered into a new loan agreement which provides the company with a facility of $266,000. The new lenders are Bioscience Ventures II LP (Rockville, USA), Cambridge BioScience Limited (Cambridge, UK) and Michael Kerins, a director of the Company. The new loan has a 2-year term. The Company has now repaid the outstanding principle of $1,900,000 on a loan to Laurus Funds. At a meeting of the Board of directors Dr. Bill Mason (Chairman) and Max Dyer Bartlett (Finance Director) resigned as directors of the Company. In addition, Michael Kerins resigned from his position as Chief Executive, but will continue to serve as a non-executive Director. Glenn Gershon, General Manager of Cytomyx LLC remains as an Executive Director. At the meeting Dr. Wei-Wu He was appointed as the new Chairman and Chief Executive with immediate effect. Dr. He is a General Partner and Co-founder of Emerging Technology Partners LLC which manages the Biosciences Ventures II fund. He was also one of the first employees of Human Genome Sciences, Inc. (NSDQ: HGSI). Dr. He has been involved in over 20 biotech companies through his career. The Company also announces today that its operating subsidiary, Cytomyx LLC, has entered into a new Europe-wide distribution agreement with Cambridge BioScience Limited. Cambridge BioScience, which was previously a subsidiary of the Company, is a well established marketing partner for life science technology companies wishing to build their business in European markets. The initial term of the appointment is 1 year, which may be extended subject to Cambridge BioScience achieving certain minimum purchase levels. Commenting on these developments, Dr. He said; "We are pleased to be able to provide the Company with this new loan facility, which will be used to provide short-term working capital. I will be exploring a number of options for the future development of the Company. Cytomyx LLC is an exciting business with a unique offering that can be of great value to its clients in the pharmaceutical industry. The appointment of Cambridge BioScience as our European distributor will provide us with extended reach into the important European market place. I would like to thank Dr. Mason and Mr. Dyer-Bartlett for their efforts on behalf of the Company, during what have at times proved to be challenging circumstances". For further information, please contact: Cytomyx Holdings plc +1 301 222 2200 Dr Wei-Wu He, Chief Executive Dr Wei-Wu He, aged 41, is currently a director or partner of the following companies and partnerships: Emerging Technology Partners Origene Technologies, Inc. Intradigm, Inc. MithraGen, Inc. Amnis, Inc. In addition, Dr He has been, within the previous five years, a director or partner of the following companies and partnerships: Aptus Pharmaceutical, Inc. InforMax, Inc FasGen, Inc. There is no further information required to be disclosed pursuant to Schedule 2 of the AIM Rules. This information is provided by RNS The company news service from the London Stock Exchange END BOALVLFLQFBBFBK |
Posted at 20/5/2006 23:40 by jweekes Another director leaves the ship! Is it sinking? The main problem I feel is that they have put all their hopes on the ion screening service, a problem in 3 ways:1. Competition, and lots of it. 2. Big Pharma want to keep this type of screening in-house if possible. 3. Nearly all clients would need the screening to be performed in FDA-approved labs, wouldn't they? CYX labs are NOT FDA APPROVED are they? Getting approval is expensive and takes ages. Why would a drug company bother with Cytomyx when the FDA would not even consider their screening results when looking to approve a drug? It has been over a year now since the service was launched and no real customers have been announced. Do they even hold the patents or licence agreements for any of their ion channels (except the Wyeth one)?!! |
Posted at 06/12/2005 23:51 by phacops Thanks RB but I hate to be right with doomed stocks. I prefer finding ones that could prosper due to good management such as Protherics. If the CEO of Cytomyx went on Dragon's Den he would be laughed out of the studio. I think that cyx will take receivership and certain directors will then take anything left private for a pittance. btw the Langbar debacle will and should make anyone leave AIM stocks such as Cytomyx well alone for a punt these days. The demise of Langbar made a splash but no-one will even hear the plip as Cytomyx gently drowns like a puppy in a grubby sack in the canal. |
Posted at 01/11/2005 10:50 by phacops Another director leaves the ship! Is it sinking? The main problem I feel is that they have put all their hopes on the ion screening service, a problem in 3 ways:1. Competition, and lots of it. 2. Big Pharma want to keep this type of screening in-house if possible. 3. Nearly all clients would need the screening to be performed in FDA-approved labs, wouldn't they? CYX labs are NOT FDA APPROVED are they? Getting approval is expensive and takes ages. Why would a drug company bother with Cytomyx when the FDA would not even consider their screening results when looking to approve a drug? It has been over a year now since the service was launched and no real customers have been announced. Do they even hold the patents or licence agreements for any of their ion channels (except the Wyeth one)?!! Personally I think it'll all be over by Christmas. |
Posted at 02/3/2005 17:57 by bernieboy Ant15 - thanks for the reply. Did you manage to find any more out?Regarding CYX it is good to see it holding its rises and moving further North. I was a bit surprised to see the positive movement with respect to the Cytocell sale though. I guess the market (which knows a lot more than me!) liked it though! |
Posted at 01/3/2005 09:21 by raldo RNS Number:1486JCytomyx Holdings PLC 01 March 2005 For immediate release 1 March 2005 CYTOMYX HOLDINGS PLC ("Cytomyx" or "the Company") Disposal of Cytocell Technologies Limited Cytomyx Holdings plc (AIM: CYX), the leading provider of drug discovery products and services, announces today that it has agreed to sell the business and assets of its wholly owned subsidiary Cytocell Technologies Limited ("Cytocell") to a consortium supporting some of Cytocell's existing management for an initial consideration of #605,000 payable in cash. The disposal of Cytocell, which develops DNA diagnostic products, will allow Cytomyx to focus on its two chosen high-growth target markets in translational medicine, exploring the link between genes and disease through the use of human biomaterials, and in its ion channel screening technologies. Under the terms of the sale agreement, the assets and liabilities of Cytocell will be transferred to the purchaser although Cytomyx will receive a royalty for four years on sales of certain products currently under development. The proceeds from the sale of Cytocell, which achieved turnover of #883,000 in the year to 30 September 2004, are expected to balance its book debt in Cytomyx' accounts and generate cash for expansion of its core product offerings. The financial results for Cytocell Technologies Limited for the year ended 30th September 2004 were as follows. Turnover #883,697 Gross profit #663,801 Net loss for the financial year (#197,822) Net liabilities (#281,599) Mike Kerins, Chief Executive of Cytomyx, commented: "Cytocell is a good business but it is no longer core to our strategy. Its disposal will allow us to invest further in our chosen high growth markets. We see great opportunities for our business in the emerging field of translational medicine where pharmaceutical researchers are using human biomaterials to validate new drug targets and provide a clearer understanding of the effectiveness of experimental drugs in clinical trials. We are uniquely placed with our biorepository of human tissue samples and associated technologies such as tissue microarrays to become a preferred supplier to the pharmaceutical industry of high value solutions that better inform their decision-making in pharmaceutical development. We are also continuing to invest in our world-leading ion channel technology platform. We are continuing the development of our range of ion channel cell lines and plan to extend our capabilities in this area through the introduction of an important new screening service in the coming months." For further information, please contact: Cytomyx Holdings plc 01223 508191 Mike Kerins, Chief Executive Buchanan Communications 020 7466 5000 Mark Court/Mary-Jane Johnson The Wall Street Group +1 212 888 4848 Ron Stabiner Notes for editors About Cytomyx Holdings plc Cytomyx Holdings plc is a rapidly growing life science company based in Cambridge, UK. Its three operating subsidiaries - Cytomyx Ltd, Clinomics Biosciences, Inc. and Cambridge BioScience Ltd - develop and market a wide range of products and services to the pharmaceutical and academic research markets. Cytomyx is listed on the AIM market of the London Stock Exchange. For more information please visit www.cytomyx-holdings This information is provided by RNS The company news service from the London Stock Exchange END DISDVLFLELBZBBL |
Posted at 19/2/2005 10:18 by hell_fire_corruption I'm after a little infomation please, I've held CYX for a couple of years and lost interest just taken a look at the price and was rather amased to see the price jump could somebody please let me know what happened to make the price jump so much |
Posted at 16/2/2005 18:31 by ant15 Bernie I do not hold Billam plc I used to, but got my fingers well and truly burnt.billam ag was a subsidiary of Billam plc which was sold on about 18 months ago to a chap called hoskins.according to the scrolling news on Billam ag CYX investment on 13.1.04 I dont know if it held before that.I will ask questions and find out a bit more if I can. |
Posted at 19/1/2005 10:53 by raldo Cytomyx Holdings PLC19 January 2005 For immediate release 19 January 2005 CYTOMYX HOLDINGS PLC ('Cytomyx' or 'the Company') Preliminary results for the year ended 30 September 2004 Cytomyx Holdings plc (AIM: CYX), the leading provider of drug discovery products and services, is pleased to announce its full year results for the year ended 30 September 2004. Highlights: Turnover up 11 per cent at £5.66 million (2003: £5.10 million) Gross profit up 32 per cent at £3.38 million (2003: £2.56 million) Gross profit margin 60 per cent (2003: 50 per cent) Net loss £915,661 (2003: net loss £414,051), reflecting investment in new US operations Successful institutional Placing to raise £1.9 million completed January 2004 Acquisition of Clinomics Biosciences Inc., a US company with a major collection of highly characterised human tissue samples, in January 2004 Clinomics' new Oncology Cell Signalling Database licensed to AstraZeneca in March 2004 Significant expansion in the number of ion channel cell lines from 2 to 17 Collaboration with Moffit Cancer Center, Florida, in July 2004 Highlights post the year end: Molecular Probes distribution contract reinstated Clinomics' integration with Cytomyx Ltd and equity fund raising facility approved in December 2004 $2.5 million convertible loan facility arranged through Laurus Master Fund in December 2004 Commenting on the results, Mike Kerins, Cytomyx' Chief Executive, said: 'We are delighted with the progress made during the year, reflected in the fact that we now work regularly for eight out of the top ten pharmaceutical companies worldwide. The developments post the year end, including additional flexibility in financing the company, together with current trading give us confidence in the year ahead.' For further information, please contact: Cytomyx Holdings plc 01223 508191 Mike Kerins, Chief Executive Buchanan Communications 020 7466 5000 Mark Court/Mary-Jane Johnson The Wall Street Group +1 212 888 4848 Ron Stabiner CYTOMYX HOLDINGS PLC Preliminary Statement for the year ended 30 September 2004 CHAIRMAN'S STATEMENT Cytomyx has had an exciting year of growth and consolidation. This has included not only a strengthening of gross profit margins through new high value contracts in the second half of the financial year, but also the acquisition in January 2004 of US-based Clinomics Biosciences Inc ('Clinomics'), a company whose unique capabilities give us the potential for substantial growth in future years. As a result of this acquisition, we have been pleased to welcome Stephen Turner, the Founder and CEO of Clinomics, to our Board. Mr Turner has a distinguished track record in the life science industry and will be a major contributor to the future direction of the group. The acquisition of Clinomics will facilitate a number of plans that we have to strengthen our offering of drug discovery technology solutions on a global basis. During the year, Cytomyx Ltd has greatly accelerated its progress in the development of high value products used in drug discovery. A major effort to develop recombinant cell lines that express ion channel proteins has been highly successful and we are now recognised as the world's leading developer of these systems. These high value products are used to develop new treatments in areas such as pain, epilepsy and heart disease, as well as being widely used to test new drugs for their potential to cause serious cardiac toxicity side effects. These products have shown considerable promise for future revenues. Clinomics has established a very large collection of human tissue samples, spanning most of the major diseases currently being investigated by the pharmaceutical industry. All of the samples in the collection are linked to detailed clinical information from the donor patient and these are used by our clients to discover new genes involved in disease progression. Since January, we have relocated Clinomics to a new facility in Albany, New York, and made rapid strides in expanding its offering of products to the pharmaceutical industry. During the year we were successful in securing a number of major contracts with leading pharmaceutical companies, including AstraZeneca. In addition, we entered into a major new initiative to develop new Cancer Tissue MicroArrays (our core technology) with the prestigious Moffitt Cancer Centre in Florida. We believe that there are many significant synergies between the Clinomics and Cytomyx Ltd businesses and, in order to best exploit these, it is our intention to merge the two companies into a single global business unit early in 2005. While the integration of Clinomics is not yet complete, early indications are that this will be a powerful and accretive acquisition of the Cytomyx group. Cambridge BioScience Ltd continued to perform well, and, after extensive negotiation, we were delighted to announce re-attaining the distribution contract for Molecular Probes following its sale to Invitrogen Corporation. Cambridge BioScience Ltd during the year has also initiated a number of exciting new distribution contracts with innovative US suppliers. Fund raising Interest in the group's key strategic products and services has been strong during the year. We also recognise the need to strengthen our position in the critical US marketplace, which accounts for around 50% of global pharmaceutical R&D expenditure. The acquisition of Clinomics was our first major step towards strengthening our activities in the US. As a result of this acquisition, we have received interest from several US-based investors and in December we agreed to an offer of a $2.5m convertible loan facility from Laurus Funds that will expand available working capital necessary for our increased level of activity in the US. We anticipate continued growth through the group in light of our new US activities. Financial The group grew its revenues by more than 11% to £5,664,252 in 2004 from £5,101,315 in 2003. This growth came from new and acquired activities, some of the growth being temporarily masked by the temporary loss of the Molecular Probes contract and the decision to wind down some low margin activities such as DNA sequencing services. Gross profit has grown to £3,383,859 from £2,560,138 in 2003. Notwithstanding the net loss in the first half which, to a large extent, reflected costs related to the investment in and relocation of Clinomics, our second half provided firm evidence of increasing gross profit margins including the positive impact of the Clinomics' acquisition. Dividend In light of the loss for the year, the early stage nature of the company and the ongoing need for investment to grow the Cytomyx Group, the Board does not recommend the payment of a dividend for the year. Summary The group has continued to focus on developing world class technologies for use in pharmaceutical R&D and we are now seeing strong demand for these key products. The strategically important acquisition of Clinomics puts us in a leading position in a major growth market and provides access to the critical US market. We have also seen strong interest from the US investment community who have taken notice of our increasing focus on business opportunities in North America. We believe 2005 will be a year of significant consolidation, growth and development of our increasingly successful pharmaceutical solutions business. Dr. Bill Mason Chairman 19 January 2005 CONSOLIDATED PROFIT AND LOSS ACCOUNT Year ended 30 September 2004 Note 2004 2003 £ £ TURNOVER Existing operations 4,993,523 5,101,315 Acquisitions 670,729 - Turnover - continuing operations 5,664,252 5,101,315 Cost of sales (2,280,393) (2,541,177) Gross profit 3,383,859 2,560,138 Distribution costs (137,300) (152,937) Administrative expenses (4,218,815) (2,757,265) Other operating income - 15,969 OPERATING LOSS Existing operations (814,880) (334,095) Acquisitions (157,376) - Operating loss - continuing operations (972,256) (334,095) Restructuring costs - (118,086) LOSS ON ORDINARY ACTIVITIES BEFORE INTEREST (972,256) (452,181) Interest receivable and similar income 22,124 7,592 Interest payable and similar charges (46,960) (32,328) LOSS ON ORDINARY ACTIVITIES BEFORE TAXATION (997,092) (476,917) Tax on loss on ordinary activities 81,431 62,866 LOSS FOR THE FINANCIAL YEAR (915,661) (414,051) Loss per ordinary share (pence) 2 (2.42) (1.59) Diluted loss per ordinary share (pence) 2 (2.42) (1.59) CONSOLIDATED BALANCE SHEET 30 September 2004 Note 2004 2003 £ £ FIXED ASSETS Intangible assets 4,479,363 1,233,895 Tangible assets 1,615,138 1,069,576 6,094,501 2,303,471 CURRENT ASSETS Stocks 477,815 375,799 Debtors Due after more than one year 60,600 60,600 Due within one year 964,402 1,184,044 Short term investments 450,000 - Cash at bank and in hand 387,553 414,529 2,340,370 2,034,972 CREDITORS: amounts falling due within one year (1,330,278) (869,695) NET CURRENT ASSETS 1,010,092 1,165,277 TOTAL ASSETS LESS CURRENT LIABILITIES 7,104,593 3,468,748 CREDITORS: amounts falling due after more than one year (880,194) (1,158,327) 6,224,399 2,310,421 CAPITAL AND RESERVES 3 Called up share capital 1,044,809 701,230 Share premium account 5,107,518 3,478,203 Share capital to be issued 675,817 - Merger reserve 2,089,460 (99,900) Foreign exchange reserve (8,432) - Profit and loss account (2,684,773) (1,769,112) EQUITY SHAREHOLDERS' FUNDS 6,224,399 2,310,421 COMPANY BALANCE SHEET 30 September 2004 Note 2004 2003 £ £ FIXED ASSETS Tangible assets 2,495 - Investments 3,394,016 102,000 3,396,511 102,000 CURRENT ASSETS Debtors Due after more than one year 4,654,580 3,856,571 Due within one year 22,364 27,287 Short term investments 450,000 - Cash at bank and in hand 74,967 6,180 5,201,911 3,890,038 CREDITORS: amounts falling due within one year (221,309) (42,500) NET CURRENT ASSETS 4,980,602 3,847,538 TOTAL ASSETS LESS CURRENT LIABILITIES 8,377,113 3,949,538 CAPITAL AND RESERVES 3 Called up share capital 1,044,809 701,230 Share premium account 5,107,518 3,478,203 Share capital to be issued 675,817 - Merger reserve 2,189,360 - Profit and loss account (640,391) (229,895) EQUITY SHAREHOLDERS' FUNDS 8,377,113 3,949,538 CONSOLIDATED CASH FLOW STATEMENT Year ended 30 September 2004 Note 2004 2003 £ £ Net cash outflow from operating activities 4 (122,629) (920,219) Returns on investments and servicing of finance 5 (24,836) (24,736) Taxation 5 58,338 10,880 Capital expenditure and financial investment 5 (617,755) (74,002) Acquisitions 5 (243,003) (369,982) Net cash outflow before management of liquid resources and financing (949,885) (1,378,059) Management of liquid resources 5 (450,000) - Financing 5 1,372,909 1,868,502 (Decrease) increase in cash in the year 6 (26,976) 490,443 RECONCILIATION OF NET CASH FLOW TO MOVEMENT IN NET DEBT 2004 2003 £ £ (Decrease) increase in cash in the year (26,976) 490,443 Cash outflow from decrease in lease financing 44,142 24,320 Cash outflow from decrease in loan notes 365,464 25,000 Cash inflow from new bank loan - (100,000) Cash outflow from increase in liquid resources 450,000 - Change in net debt resulting from cash flows 832,630 439,763 Loans and finance leases acquired with subsidiary (48,789) - New finance leases (34,129) (46,243) New loan notes - (1,180,000) Change in net debt 749,712 (786,480) Net debt at beginning of year (911,827) (125,347) Net debt at end of year (162,115) (911,827) STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES Year ended 30 September 2004 2004 2003 £ £ Loss for the financial year (915,661) (414,051) Currency translation difference on foreign currency net investments (8,432) - Total gains and losses since last annual report (924,093) (414,051) NOTES The information set out above does not constitute the Company's statutory accounts for the years ended 30 September 2004 or 2003, but is derived from those accounts, and is prepared on the basis of the accounting policies as set out in the most recently published set of annual financial statements. Statutory accounts for 2003 have been delivered to the Registrar of Companies, and those for 2004 will be delivered following the Company's Annual General Meeting. The auditors have reported on those accounts; their report was unqualified and did not contain a statement under section 237(2) or (3) of the Companies Act 1985. LOSS PER ORDINARY SHARE The diluted loss per share takes into account the dilutive effect of share options. Ordinary shares which are potentially issuable are only included in the calculation of diluted earnings per share if their issue would decrease net profit per share or increase net loss per share. The exercise of share options does not increase the basic loss per share and therefore the basic and diluted loss per share remain the same. The calculation of basic loss per ordinary share is based on a loss of £915,661 (2003 - £414,051) and on 37,878,653 (2003 - 26,103,565) ordinary shares being the weighted average number of ordinary shares in issue during the year. RECONCILIATION OF MOVEMENTS IN SHAREHOLDERS' FUNDS AND STATEMENT OF MOVEMENTS ON RESERVES Called up Share Share Foreign Profit and share premium capital to Merger exchange loss capital account be issued reserve reserve account Total £ £ £ £ £ £ £ Group Balance at 1 October 2003 701,230 3,478,203 - (99,900) - (1,769,112) 2,310,421 Loss for the year - - - - - (915,661) (915,661) Shares issued 343,579 1,761,800 - 2,189,360 - - 4,294,739 Shares to be issued - - 675,817 - - - 675,817 Currency translation differences on foreign currency net investments - - - - (8,432) - (8,432) Costs set against share premium - (132,485) - - - - (132,485) Balance at 30 September 2002 1,044,809 5,107,518 675,817 2,089,460 (8,432) (2,684,773) 6,224,399 Company Balance at 1 October 2003 701,230 3,478,203 - - - (229,895) 3,949,538 Loss for the year - - - - - (410,496) (410,496) Shares issued 343,579 1,761,800 - 2,189,360 - - 4,294,739 Shares to be issued - - 675,817 - - - 675,817 Costs set against share premium - (132,485) - - - - (132,485) Balance at 30 September 2002 1,044,809 5,107,518 675,817 2,189,360 - (640,391) 8,377,113 Share capital to be issued represents Deferred Contingent Consideration in relation to the acquisition of Clinomics Biosciences Inc. NET CASH OUTFLOW FROM OPERATING ACTIVITIES 2004 2003 £ £ Operating loss (972,256) (334,095) Depreciation charge 260,389 196,350 Loss on disposal of fixed assets 1,150 - Amortisation of goodwill and intangibles 204,953 63,016 Exceptional restructuring costs - (118,086) Decrease (increase) in debtors 333,737 (658,770) Increase in stocks (102,016) (160,803) Increase in creditors 151,414 92,169 Net cash outflow from operating activities (122,629) (920,219) ANALYSIS OF CASH FLOWS FOR HEADINGS NETTED IN THE CASH FLOW STATEMENT 2004 2003 £ £ Returns on investments and servicing of finance Interest received 22,124 7,592 Interest paid (7,227) (32,328) Interest element of finance lease rental payments (39,733) - Net cash outflow from returns on investments and servicing of finance (24,836) (24,736) Taxation Research and development tax credit 58,338 10,880 Capital expenditure and financial investment Payments to acquire tangible fixed assets (512,972) (57,073) Receipts from the sale of fixed assets 6,611 - Payments to acquire intangible fixed assets (111,394) (16,929) Net cash outflow from capital expenditure and financial investment (617,755) (74,002) Acquisitions Purchase of trade and assets of Cambridge BioScience Limited - (319,982) Purchase of trade and assets of Cytocell Limited - (50,000) Purchase of Clinomics Biosciences Inc (236,460) - Overdraft acquired with subsidiary (6,543) - (243,003) (369,982) Management of liquid resources Increase in short-term investments (450,000) - Financing Proceeds from issue of ordinary share capital 1,915,000 2,269,000 Cost of issuing ordinary share capital (132,485) (451,178) Capital element of finance lease rental repayments (44,142) (24,320) Repayment of loan notes (365,464) (25,000) New bank loan - 100,000 Net cash inflow from financing 1,372,909 1,868,502 ANALYSIS OF CHANGES IN NET DEBT Acquisition At 1 excluding Other At 30 October Cash cash and non-cash September 2003 flows overdraft changes 2004 £ £ £ £ £ Cash at bank and in hand 414,529 (26,976) - - 387,553 Debt due after one year (1,145,000) 224,103 (17,428) 83,025 (855,300) Debt due within one year (110,000) 141,361 (31,361) (83,025) (83,025) Finance leases (71,356) 44,142 - (34,129) (61,343) (1,326,356) 409,606 (48,789) (34,129) (999,668) Short term investment - 450,000 - - 450,000 Net debt (911,827) 832,630 (48,789) (34,129) (162,115) This information is provided by RNS The company news service from the London Stock Exchange |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
